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Abstract
Chromosomal rearrangements with duplication of the lamin B1 (LMNB1) gene underlie autosomal dominant adult-onset
demyelinating leukodystrophy (ADLD), a rare neurological disorder in which overexpression of LMNB1 causes progressive central
nervous systemdemyelination. However, we previously reported anADLD family (ADLD-1-TO)without evidence of duplication or
other mutation in LMNB1 despite linkage to the LMNB1 locus and lamin B1 overexpression. By custom array-CGH, we further
investigated this family and report here that patients carry a large (∼660 kb) heterozygous deletion that begins 66 kb upstream of
the LMNB1 promoter. Lamin B1 overexpression was conﬁrmed in further ADLD-1-TO tissues and in a postmortem brain sample,
where lamin B1 was increased in the frontal lobe. Through parallel studies, we investigated both loss of genetic material and
chromosomal rearrangement as possible causes of LMNB1 overexpression, and found that ADLD-1-TO plausibly results from an
enhancer adoption mechanism. The deletion eliminates a genome topological domain boundary, allowing normally forbidden
interactions between at least three forebrain-directed enhancers and the LMNB1 promoter, in line with the observed mainly
cerebral localization of lamin B1 overexpression andmyelin degeneration. This second route to LMNB1 overexpression and ADLD
is a new example of the relevance of regulatory landscape modiﬁcations in determining Mendelian phenotypes.
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Introduction
Autosomal dominant adult-onset demyelinating leukodystro-
phy (ADLD, OMIM #169 500) is a rare neurological disorder char-
acterized by genetically determined, progressive loss of white
matter (WM) within the central nervous system (CNS) (1). Most
forms of leukodystrophy are early onset, appearing in childhood.
In contrast, the clinical onset of ADLD occurs in the fourth or
ﬁfth decade, usually with symptoms of autonomic dysfunction,
followed by ataxia and cognitive impairment that signal pyram-
idal and cerebellar involvement. Typical changes associated
with demyelination are observed in brain and spinal cord WM
by MRI (2).
The familial occurrence of ADLD has been reported in link-
age with chromosome 5q23-31 in a dozen families of broadly
different ethnic origins (2–10), including one Italian family that
we described in 2010 (11). Genetic analyses ultimately led to the
identiﬁcation by Padiath et al. of heterozygous duplications of
the lamin B1 gene (LMNB1, chr5q23.2) as the disease-causing
mutations in ADLD (9). Thus the disease is caused by increased
levels of lamin B1 protein produced by the presence of a func-
tional extra copy of the LMNB1 gene, making ADLD as part of a
growing number of neurological disorders caused by gene copy
number variation.
The B-type lamins are members of the intermediate ﬁla-
ment protein superfamily and play a major role in forming
the nuclear lamina lining the inner nuclear membrane. Lamin
B1 appears to play two distinct functions in the vertebrate nu-
cleus: a structural role in maintaining nuclear integrity (12–14),
and a regulatory role in DNA replication and gene expression
(15,16). Overexpression of lamin B1 in human (HEK 293) andmur-
ine (NG2a) cell lines has been reported to increase nuclear rigid-
ity, a feature also present in nuclei obtained from ADLD skin
ﬁbroblasts (14).
Although lamin B1 is ubiquitously expressed it appears that
oligodendrocytes, the cells responsible for myelin deposition
in the CNS, are particularly sensitive to LMNB1 gene dosage.
In these cells, lamin B1 overexpression perturbs both nuclear
architecture and gene expression, leading to demyelination
through a complex pathway that involves downregulation of
proteolipid protein (PLP, a major myelin sheath component
whose duplication leads to Pelizaeus-Merzbacher Disease,
OMIM#300401) by reduced Yin-Yang 1 transcription factor (TF)
binding (17,18).
Since 2010, we have been studying a multigenerational Italian
family, designated ADLD-1-TO, in which affected members present
clinical andneuroradiological signscompatiblewithADLD (19).How-
ever, subtle differences were noted, such as the absence of auto-
nomic dysfunction at onset and relative sparing of cerebellar WM
(11,20). By linkage analysis, we mapped the disease to chromosome
5q23.2-q23.3, within a 4.3 Mb genomic region containing LMNB1. We
demonstrated that lamin B1 mRNA expression in ADLD-1-TO pa-
tients was increased and comparable to the expression levels
found in ADLD patients with LMNB1 duplication (9,21,22). However,
we found neither duplication, mutation nor deletion in LMNB1 (11).
This paper reports on our efforts to reach a genetic diagnosis
in the ALDL-1-TO family.
Results
Increased expression of LMNB1 in ADLD-1-TO tissues
Overexpression of lamin B1 is a hallmark of ADLD (9,19,22) but
the most disease-relevant tissue, the brain, is also the least
accessible. We obtained a postmortem brain specimen follow-
ing autopsy of patient VI-7 (Fig. 1A) who died at the age of
56 due to ADLD. Western blot analysis of a frontal lobe (FL) ex-
tract showed a robust increase in lamin B1 protein (about 7-
fold) with respect to a control postmortem brain specimen
(Fig. 1B). Bearing in mind that MRI in ADLD-1-TO patients
shows that forebrain-derived structures are affected, but not
the cerebellum (hindbrain-derived) (19,21), we analyzed LMNB1
protein levels also in the cerebellum. Comparison between
FL and cerebellar (C) LMNB1 protein levels by western blot
demonstrated that in the patient, lamin B1 is about 3.6 times
more abundant in FL compared to the control [FL/C ratio of
0.81 versus 0.22 in gray matter (GM), and 1.23 versus 0.36 in
WM, Fig. 1B].
Lamin B1 overexpression was also detected in proxy tissues
from patients: by real-time polymerase chain reaction (PCR),
lamin B1 transcripts were increased 2- to 3-fold in ﬁbroblasts
from patient VI-1 (Fig. 1C; mean ± standard error = 3.15 ± 0.73;
P < 0.0001) and in PAXgene-stabilized whole blood obtained
frompatientsVI-7 andVII-4 (Fig. 1C,mean± standard error = 2.04 ±
0.31; P < 0.0001) with respect to healthy controls.
Altered physical properties of nuclei from
ADLD-1-TO cells
In ADLD with LMNB1 duplication, the surplus lamin B1 protein
is found mostly in the nuclear lamina, leading to alterations
in nuclear morphology and increased nuclear membrane rigid-
ity (14,17). In ﬁbroblasts from patient VI-1, we observed: (i)
lamin B1 protein accumulation within the nuclear lamina by
immunocytochemistry (Fig. 1D); (ii) abnormal nuclear morph-
ology with blebs and invaginations by ﬂuorescence microscopy
(Fig. 1D) and (iii) ∼44% increase in nuclear rigidity compared to
control nuclei by atomic force microscopy (AFM) indentation
(Fig. 1E; P < 0.05), with a signiﬁcant increase of Young’s elastic
modulus (average ± SEM: 707.0 ± 159.1 Pa) compared to con-
trol nuclei (421.9 ± 60.6 Pa; P = 0.02, Student’s t-test. Data not
shown).
Identiﬁcation of a large deletion 66 kb upstream
of LMNB1in ADLD-1-TO
As the experimental evidence indicated that LMNB1 over-
expression occurred in ADLD-1-TO in the absence of LMNB1
mutations, we searched for disruptions that might cause aber-
rant LMNB1 transcriptional control. Custom array CGH ana-
lysis of a 2.2 Mb region of chromosome 5 centered on LMNB1
identiﬁed a 660 kb deletion (hg19/chr5:125 385 805–126 043
053), with the closest deletion boundary located 66 kb up-
stream of LMNB1 (Fig. 2A). The deletion was conﬁrmed by
FISH analysis (Supplementary Material, Fig. S1). This deletion
was not present in the Database of Genomic Variants (http://
dgv.tcag.ca/dgv/app/home), and not detected in 100 Italian
healthy subjects.
Nucleotide sequences of the deletion boundaries contained
Alu elements: AluSx1 at the centromeric boundary and AluSz at
the telomeric boundary (Fig. 2B). These elements share a 23-bp
region of microhomology, suggesting Alu-derived microhomol-
ogy-mediated break-induced replication (MMBIR) was respon-
sible for the rearrangement (23,24).
The chromosomal rearrangement upstream of LMNB1 led to
the deletion of three genes (Fig. 2B), the closest to LMNB1 being
PHosphorylated Adaptor for RNA eXport (PHAX, OMIM *604924),
which encodes a 394 amino acid protein involved in snRNA
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export from the nucleus. The second deleted gene is ALdehyde
DeHydrogenase 7 family, member A1 (ALDH7A1, OMIM *107323)
which encodes an enzyme involved in lysine metabolism; reces-
sive mutations cause pyridoxine-dependent epilepsy (OMIM
#266100). The most distal deleted gene is GRAM domain
containing 3 (GRAMD3) which encodes a broadly expressed 432
amino acid protein found in cytoplasmicmicrotubules. Although
not associated with any neuropathology to our knowledge, we
note that it is expressed in oligodendrocyte precursors (www.
genecards.org).
Figure 1. ADLD-1-TO family, LMNB1 expression and nuclear abnormalities. (A) Simpliﬁed ADLD-1-TO family tree. Most of the healthy subjects have been omitted. A short
line over the patient symbol indicates DNA was available for the study. (B) Western blot analysis of LMNB1 from FL (left) and cerebellum (center) GM and WM. Twenty
micrograms of brain protein extracts from a control and an ADLD-1-TO (VI-7) patient were analyzed. The histogram (right) shows LMNB1 protein levels detected by
western blot as a ratio between FL and cerebellum (C) (loading control alpha-tubulin); our patient presented an FL/C ratio in GM of 0.81 versus 0.22 in the control, and
in WM of 1.36 versus 0.36. (C) Real-time PCR Lamin B1 (LMNB1) levels measured in RNA derived from ﬁbroblasts or PAXgene-stabilized blood. Both experiments are
normalized versus the HMBS gene and the value on the y-axis represents the dose calculated with the 2−ΔΔCt method. Error bars indicates Standard Error. ***P < 0.001,
Mann–Whitney two-tailed test. (D) Representative maximal projections of z-stack confocal images of nuclei from control and ADLD-1-TO human skin ﬁbroblasts (VI-
4) immunostained for LMNB1. Scale bar: 10 µm. (E) Nuclear stiffness analysis by AFM was performed on nuclei extracted from quiescent control and ADLD-1-TO
ﬁbroblasts (VI-4). Box plot shows nuclear stiffness values. A total of 88 ﬁbroblast nuclei from three age-matched control subjects (n = 34 nuclei) and one ADLD-1-TO
(n = 54 nuclei) patient were analyzed in three independent experiments. *P < 0.05, Mann–Whitney Rank Sum Test.
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Analysis of the deleted genes effect on LMNB1 expression
GRAMD3, ALDH7A1 and PHAX appear to be broadly expressed in
humans, including in adult brain (http://www.genecards.org/).
Although there is no evidence of a pathway linking these
genes to LMNB1 regulation, we cannot completely exclude that
they play a role in ADLD or in lamin B1 gain of expression.
For the current study, we established a cellular model that
mimicked the effects of the deletion by reducing the amount
of GRAMD3, ALDH7A1 and PHAX transcripts. We then observed
the effects on lamin B1 expression. We generated simultan-
eous triple-gene haploinsufﬁciency in normal human ﬁbroblasts
by small interfering RNA (siRNA) transfection and measured
lamin B1 transcripts. Although mRNA levels of GRAMD3,
ALDH7A1 and PHAX were reduced by at least 50%, and there-
fore comparable to those expected in our patient-derived ﬁbro-
blasts, LMNB1 expression was unchanged (Supplementary
Material, Fig. S2).
Normal and patient-speciﬁc long-range interactions
with the LMNB1 promoter
To identify interactions between the rearranged upstream gen-
omic region and the LMNB1 promoter that might determine the
gain of lamin B1 expression, we performed circular chromo-
some conformation capture (4C) analyses in ﬁbroblasts of
ADLD-1-TO patient VI-1 and a healthy control, using LMNB1
promoter as bait. This technique was developed to identify
physical interactions genome-wide from any given genomic lo-
cation (25,26). We identiﬁed four genomic regions interacting
with the LMNB1 promoter: regions A, B, C and D (Fig. 3A, Sup-
plementary Material, Fig. S3 and 4). Region A was identiﬁed in
both patient and control, and mapped to ∼120 kb 5′ of the
LMNB1 promoter on the wild type allele. Region A is deleted
in the mutant chromosome, but one copy remains available
for interaction in the patient. The other three interacting re-
gions were identiﬁed only in the patient: regions B, C and D
mapped to 0.77, 1.94 and 2.0 Mb upstream of the LMNB1 pro-
moter respectively (Fig. 3A). As a consequence of the deletion,
the three regions are relocated closer to the LMNB1 promoter in
the patient.
Analysis and validation of 4C contacts
We analyzed regions A, B, C and D by in silico prediction of enhan-
cer activity using the ENCODE tracks at UCSC (www.genome.ucsc.
edu), and identiﬁed putative enhancer features in regions A and B,
but not in regions C and D. Region A shows digital DNaseI hyper-
sensitive sites and a potential site for PU1 TF binding; region B
has DNaseI hypersensitive sites and putative binding motifs
for BCL11A, FOXA1, GATA3, Max, NANOG, POU5F1, SP1, USF-1,
USF-2 and Yin Yang 1 TFs (Fig. 3B). None of these regions is evolu-
tionarily conserved.
Figure 2. Characterization of a large deletion 66 kb upstream of LMNB1. (A) Custom a-CGH graphical output. Values on top represent the log ratio of the probes (log2
intensity of Cy5/Cy3 ﬂuorochromes): expected values are from −0.7 to −1 for a deletion, 0 (zero) for normal and 0.5–1 for a genomic duplication. The position of the
ﬁrst normal probe is reported on the left, along with a schematic representation of the genes involved (gray rectangles). (B) Schematic of the deleted genomic region
in which the deleted genes have dashed border and the arrowhead shows the transcription direction. The position of the primers used to amplify and sequence the
breakpoint (not in scale) is shown (black and white arrows; F1, R1 and R2). The two Alu elements (AluSx1 and AluSz) and a (TA)n repeat are shown. Below, the
sequence of the breakpoint: a stretch of 23 identical bases are shared between the two regions (boxed).
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To test the predicted enhancers experimentally, we perfor-
med dual-luciferase reporter assays with constructs containing
regions A, B, C or D, in direct or reverse orientation, upstream
of the LMNB1 promoter (for promoter deﬁnition, see Supple-
mentary Material and Fig. S5). Following transfection of the con-
structs into HEK293T human cell line, regions A and B (in both
orientations) signiﬁcantly increased luciferase expression
(A forward= 1.97 ± 0.2; A reverse = 1.8 ± 1.6; B forward= 2.52 ± 0.25;
B reverse = 1.85 ± 0.10; mean ± standard error; P < 0.01; Fig. 3C). In
contrast, constructs containing regions C and D did not signiﬁ-
cantly affect luciferase expression (Fig. 3C). Similar results were
obtained when the same plasmids were transfected into NIH3T3
cell line (data not shown), suggesting that the enhancer activity of
regions A and B could function across species, at least in mouse
ﬁbroblasts. Following these results, regions A and B were subse-
quently referred to as enhancer region A (Enh-A) and enhancer
region B (Enh-B).
To validate and better characterize Enh-A and -B interactions
with the LMNB1 promoter, we performed nested-PCR on circular-
ized DNA which conﬁrmed that region A interacted in both
patient and control, whereas the interaction of region B was
patient-speciﬁc (Supplementary Material). In addition, for region
Figure 3. Circular chromosome conformation capture (4C) and in vitro/in vivo enhancer study. (A) Schematic of the 4C results. Summary of the log2 interactions (reads/
million) with the lamin B1 promoter (orange bars) in patient VI-1 and a control (vertical bars A–D). The deletion is shown as a black rectangle, with gray arrows
representing the involved genes and LMNB1 in orange. (B) Integrated Regulation track (modiﬁed from UCSC browser) for regions A and B (ENCODE data). Red and blue
bars represent regions A and B captured by 4C (DpnII fragments), respectively. Green bars represent enhancer-containing regions cloned to perform in vitro validation.
Gray bars represent consensus sequences for TFs; bar color intensity is proportional to the level of TF enrichment from the UCSC Uniform TFBS Track. (C) Dual
luciferase assay on HEK293T cells showing the effect of regions A–D on the LMNB1 promoter. The luciferase activity is normalized on the pGL4.10 construct containing
the LMNB1promoter alone (fold change on the y-bar) (see SupplementaryMaterial for a summaryof the vectors used). Red and blue bars show the activity of regions A and
B in forward (f) and reverse (r) orientation. Dark gray bars show the activity of regions C and D, in forward (f) and reverse (r) orientation. Error bars represent the standard
error of the mean (n.s = not signiﬁcant; *** P-value < 0.001, **P-value < 0.01; Mann–Whitney two-tailed test). (D) Transgenic mouse enhancer assay with Enh-B suggests
forebrain-speciﬁc enhancer activity at day E11.5.
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B we established that the 4C interaction occurred only in cis
by exploiting a heterozygous SNP in the LMNB1 promoter of
the patient in which the ‘C’ allele segregated with the deletion
(Supplementary Material and Fig. S6). Overall, the 4C assay to-
gether with the in silico and in vitro data suggest that the deletion
establishes an enhancer-adoption mechanism (27,28) by mono-
allelic Enh-A deletion followed by repositioning of Enh-B from
∼770 kb to ∼110 kb upstream of the LMNB1 promoter.
To determine if Enh-A and Enh-B behave as enhancers in an
in vivomurine model, we performed transgenic mouse enhancer
assays (29) with Enh-A or Enh-B linked to a minimal mouse pro-
moter and lacZ reporter gene (Hsp68-lacZ). Founder transgenic
embryos were generated and stained for lacZ reporter activity at
embryonic day 11.5. Of 17 F0 embryos with the Enh-B construct,
four showed reporter expression in the developing forebrain
(Fig. 3D). In contrast, no F0 embryos with the Enh-A showed
reporter expression (data not shown).
Genomic landscape of LMNB1 locus with topological
domains (TDs)
To validate the hypothesis that the deletion in ADLD-1-TO pa-
tients leads to enhancer adoption, we used the genome-wide
chromatin interaction data obtained by the Hi-C protocol gener-
ated by Dixon et al. (30) to analyze the genomic landscape of the
1.5 Mb region surrounding LMNB1 (http://yuelab.org/hi-c/). This
procedure identiﬁed both TDs (sub-Mb chromosomal regions
that favor enhancer-promoter interactions) and a topological do-
main boundary (TD boundary or insulator) (31) (Fig. 4) involving
LMNB1. The ﬁrst TD (TD1, chr5: 122 972 101–125 932 102) includes
Enh-B and the ZNF608, GRAMD3 and ALDH7A1 genes; the second
TD (TD2, chr5: 125 932 101–126 852 102) encompasses PHAX, Enh-
A and LMNB1. The deletion spans across TD1 and TD2, eliminat-
ing the TDboundaryelement located at chr5: 125 932 101–125 932
102, likely allowing the interaction between Enh-B and the LMNB1
promoter.
Discussion
Gene duplication, a fortuitous event caused by errors in DNA rep-
lication/recombination, represents a major positive force in gen-
ome evolution (32). However, gene duplication can also have
negative consequences, and give rise to a Mendelian disorder
such as autosomal dominant leukodystrophy. The evidence to
date, accumulated from affected families of varied ethnicity,
has pointed to duplication of the lamin B1 gene on chromosome
5 as the cause of ADLD. Although the presence of excess gene
product probably occurs in all cells throughout the body, it is in
the brain that excess lamin B1 protein does most damage byme-
chanisms that are currently being worked out.
We previously described a large Italian family with clinical
hallmarks compatible with ADLD and indeed, the disease segre-
gated with the LMNB1 locus and affected individuals showed in-
creased expression of lamin B1 mRNA and protein. Detailed
genetic analysis of the ADLD-1-TO family was negative, as no
alterations in LMNB1 structure or copy number could be found
(11). However, when we unexpectedly gained access to post-
mortem brain specimens from an ADLD-1-TO patient who suc-
cumbed to the disease, western blot analyses unequivocally
showed dramatically increased amounts of lamin B1. To our
Figure 4. LMNB1 regulatory landscape. Theheatmap shows the topological domains (TD1 andTD2) and the regulatory boundary (TDB) betweenALDH7A1 and PHAX genes.
In wild-type alleles, Enh-A interacts with the LMNB1 promoter. The ∼660 kb deletion removes Enh-A and a TDB, likely causing ‘enhancer adoption’. In this situation, three
elements may act on the LMNB1 promoter: Enh-B, identiﬁed by our 4C experiments, and two human elements, hs1643 and hs1371, annotated as enhancers in the VISTA
enhancer browser. All have a forebrain or forebrain/midbrain enhancer activity as shown by in vivo mouse enhancer assay.
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knowledge, this is the ﬁrst time the disease target organ is ana-
lyzed in this way. Further support came from the recently pub-
lished observations by Ferrera et al. regarding alterations in the
mechanical properties of the nucleus induced by lamin B1 over-
expression. In fact, ﬁbroblast-derived nuclei fromADLD-1-TO pa-
tients also showed changes in nuclear membrane rigidity and
bleb formation overlapping with those reported in LMNB1-dupli-
catedADLDpatients (14). The question remained:whatwas caus-
ing lamin B1 overexpression in the enigmatic ADLD-1-TO family?
As increased expression caused by transcriptional dysregula-
tion could obviously mimic gene duplication (33), we again ana-
lyzed our family’s DNA, this time by array-CGH (a-CGH), ﬁnally
identifying a 660 kb deletion upstream of LMNB1. Besides re-
arranging this region of chromosome 5, the deletion led to the
monoallelic loss of three genes -GRAMD3, ALDH7A1 and PHAX.
Thus, we needed to address both the effects of (i) relocating for-
merly distant DNA closer to LMNB1 and (ii) monoallelic three-
gene loss on lamin B1 gene production.
Little to nothing is known of the function of the three deleted
genes in CNS myelination, but disease connections for them or
related genes have been described. The most distant gene from
LMNB1 is GRAMD3, a protein of unknown function containing a
GRAM domain (for Glucosyltransferases, Rab-like GTPase activa-
tors and Myotubularins). We note that other proteins containing
GRAM domains, myotubularins, are altered in Charcot-Marie-
Tooth type 4B demyelinating neuropathy (34). ALDH7A1, encod-
ing an acetaldehyde-oxidizing enzyme, is mutated in autosomal
recessive pyridoxine-dependent epilepsy (OMIM#266100) (35).
PHAX, encoding a protein identiﬁed in mouse as a component
of the U snRNA export complex assembly, has recently been as-
sociated with the Pierre Robin Sequence (36,37). Although we
cannot in principle rule out that these three genes play a role in
ADLD-1-TO pathogenesis, it has to be noted that their experi-
mentally induced simultaneous single-copy loss did not affect
lamin B1 expression. In addition, we recently described an
ADLD patient with duplication not only of LMNB1 but also of
GRAMD3,ALDH7A1 and PHAX [patient BR1 in (22)]. In this patient,
the increase in lamin B1 expression was comparable to that
found in patients with LMNB1-only duplication, further suggest-
ing that copy number variation in GRAMD3, ALDH7A1 and PHAX
does not interfere with LMNB1 expression. Therefore our favored
hypothesis is that these genes act as innocent bystanders with
respect to disease pathogenesis. Such a ‘bystander effect’ has
been described, for example, in aniridia (OMIM 106210): although
a downstreamgene, ELP4, is deleted by genomic translocations in
different patients, it is not the direct cause of the diseasewhich is
instead caused by loss of a PAX6 enhancer (38).
The 4C technique was chosen to search for LMNB1 regulatory
regions relocated in ADLD-1-TO patients following the large dele-
tion. Chromosome Conformation Capture related techniques
have already been successfully applied to uncover interactions
between distant regulatory elements, as occurs with CDKN2B in
pancreatic cancer susceptibility or FOXL2 gene in blepharophi-
mosis syndrome (39–41). Although 4C identiﬁed four enhancer-
containing regions, only regions A and B were retained; regions
C and D had no enhancer-like elements according to ENCODE
and were negative by luciferase assay, and therefore excluded
from further analysis.
In silico analyses support a regulatory function for Enh-A and
Enh-B, even if not evolutionarily conserved. This ﬁnding is in
accordance with recent papers demonstrating that a large
proportion of functional enhancers is not subject to evolutionary
constraints (42,43). The ENCODE database shows that both
enhancer elements are within DNaseI hypersensitive sites, a
marker of open chromatin structure. In addition, several binding
sites for TFs are predicted for Enh-B: (i) the YY1 and Sp1 TFs,
which are active during oligodendrocyte differentiation (44,45)
and (ii) BCL11A and GATA3, which are involved in neuron mor-
phogenesis and survival of sympathetic neurons (46,47). It is an
intriguing possibility that in ADLD-1-TO LMNB1 might be placed
under the regulation of glial and neuron-speciﬁc enhancers. It
was also recently suggested that lamin B1 might be a regulator
of PLP1 myelin protein through interaction with YY1 TF (18). It
seems reasonable to hypothesize the formation of a positive
feedback loop of Enh-B with its YY1 binding site on LMNB1,
which may further increase LMNB1 expression in speciﬁc cell
types (e.g. glia in the CNS) or developmental stages. Enhancers
A and B were validated by nested-PCR on circularized DNA,
dual luciferase assay and in vivo transgenic mouse experiments.
Recent advances into the demarcation of genomes into func-
tional TDs (30) have shed further light on the consequences of the
ALDL-1-TO deletion and rearrangement. Analysis of the TDs sur-
rounding LMNB1 shows that the deletion eliminates a boundary
element that normally separates Enh-B from the LMNB1 pro-
moter. It is likely that disruption of this boundary element can
lead to enhancer adoption, i.e. following mutation, a gene
acquires a non-physiological enhancer that drives ectopic ex-
pression of the gene (31). This mechanism of TD boundary dis-
ruption, or TDBD, opens the LMNB1 promoter to interaction
with Enh-B and two VISTA enhancer regions located in TD1: (i)
human element hs1371, a forebrain-,midbrain- and limb-speciﬁc
enhancer and (ii) hs1643, a forebrain-speciﬁc enhancer (48). Over-
all, these data suggest that the chromosomal rearrangement
caused by the deletion alters the regulatory landscape of
LMNB1, in turn leading to gene overexpression and disease.
Consistent with the pattern of activity of Enh-B, hs1371 and
hs1643, MR imaging in ADLD-1-TO patients showed that fore-
brain-derived structures are affected, but the cerebellum (hind-
brain-derived) is spared, a telling difference with ADLD families
with LMNB1 duplication, where WM throughout the brain
degenerates (20,21).
In a patient’s brain, we found a greater increase in lamin B1
protein in the FL compared to the cerebellum (about 3.6 fold
both in gray and in WM); these data, however, are limited by
the availability of a single sample and by the advanced stage of
the disease, whose effect on lamin B1 levels are poorly known,
and need to be conﬁrmed if further brain samples become avail-
able. Taken together, these results are consistent with the pro-
posed pathogenic mechanism and the demyelinating lesions in
the ADLD-1-TO kindred.
Position effects, notably enhancer adoption and enhancer
loss, are among an emerging group of disease-causing mechan-
isms. Examples of enhancer adoption are Liebenberg syndrome
(MIM 186550), a homeotic arm-to-leg transformation, in which
deletion and rearrangement brings two active enhancers closer
to the PITX1 (paired-like homeodomain 1) promoter (28,31) or ho-
loprosencephaly spectrum disorder and severe upper limb syn-
dactyly with lower limb synpolydactyly due to the relocation of
the SHH transcription unit near a limb bud enhancer (49). Instead
enhancer loss occurs in Léri-Weill syndrome and BPES (Blephar-
ophimosis, ptosis, epicanthus inversus syndrome), in which
deletions of SHOX (Léri-Weill) or FOXL2 (BPES) enhancers are re-
ported (50,51). A recent study demonstrated that in up to 11% of
all deletions reported in the DECIPHER database of chromosomal
imbalances, disease phenotypes can partly be explained by
enhancer adoption (25). Mutations in regulatory regions may be
highly underestimated, considering the ENCODE estimate that
at least 20% of the human genome, which represents about
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seven times the amount of DNA coding for exons (2.9%), is in-
volved in regulatory functions (52).
In conclusion, we describe an ADLD family in which disease
pathogenesis is caused by overexpression of the lamin B1 gene
in the brain. However, in this family ADLD is not caused by the
‘classical’ molecular mechanism of LMNB1 duplication, but by a
deletion upstream of LMNB1 that destroys a TD boundary and
brings heterologous forebrain-speciﬁc enhancers to act upon
the LMNB1 promoter. Genomic alterations that change the regu-
latory landscape are emerging determinants of Mendelian phe-
notypes and, as our experience shows, need to be taken into
account when screening for mutations in these diseases.
Materials and Methods
Patients
A simpliﬁed pedigree of ADLD-1-TO family is reported in Fig-
ure 1A. Signs, symptoms and MRI ﬁndings have been described
elsewhere (11). Genomic DNAwas already available from differ-
ent family members (black dash above the symbol in Fig. 1A).
For this work, we obtained: (i) PAXgene-stabilized blood samples
(Qiagen, Mannheim, Germany) from two patients (VI-7; VII-4); (ii)
ﬁbroblasts froma skin biopsyof patientVI-1; (iii) autopsy samples
from patient VI-7. Control hippocampal tissue was obtained
at autopsy from six patients with no history of seizures or
other neurological diseases. All autopsies were performedwithin
12 h after death. The study was approved by the DSM-ChUB
Internal Review Board. Informed consent was obtained for the
use of blood and skin samples, brain tissue and for the access
to medical records for research purposes. Tissue was obtained
and used in compliance with the Declaration of Helsinki.
Array comparative genomic hybridization and
breakpoint identiﬁcation
Two patients, VI-1 and VI-3 (Fig. 1A), were tested for deletion/du-
plication by custom a-CGH assay designed using the Agilent eAr-
ray tool on an 8 × 15 K support (https://earray.chem.agilent.com/
earray/, Agilent Technologies, Santa Clara, California, USA). We
selected a ∼2.2 Mb region between positions 125 010 000 and 127
269 000 on chromosome 5 (assembly GRCH37/hg19) with an aver-
age resolution of one probe every ∼170 bp. Slides were scanned
on a G2565BA scanner and analyzed using Agilent CGH Analytics
software ver. 4.0.81 (Agilent Technologies).
Array-CGH data were validated using FISH analysis on LCLs
metaphase preparations from patient VI-3, using BAC probes
RP11–1123C14 and RP11–1031D8 spanning the deleted region,
and RP11–322L12 and RP11–638F8 overlapping the centromeric
and telomeric breakpoint, respectively (Supplementary Material,
Fig. S1). Real-time PCR was also performed to evaluate GRAMD3
gene copy number under standard conditions (exon 2, primers:
5′-ggtgtggaggagaaaaagaaagc; 5′-ggagtccgcctccacagat; TaqMan
probe: 6-FAM-tgcaggtcgccaaca-Quencher). The same real-time
PCR was used to screen 100 Italian healthy controls to exclude
the deletion was a rare local polymorphism.
Deletion breakpoints were identiﬁed by PCR-ampliﬁcation
with primers F1 and R1 (Supplementary Material, Table S1),
using the LA Taq PCR Kit (Takara Bio Inc., Otsu, Shiga 520–2193,
Japan) in a ﬁnal volume of 25 µl under the following conditions:
60 ng genomic DNA, 1× Buffer, 0.4 m dNTPs, 2.5 m MgCl2,
0.5 µM of each primer and 1.25 U of LA Taq polymerase. Cycling
conditions were: 94°C for 1 min, 30 cycles at 98°C for 10 s, 62°C
for 10 s and 68°C for 6 min, and a ﬁnal extension at 72°C for
10 min. Polymerase chain reaction was followed by Sanger se-
quencing with primer R2 on an ABI-Prism 3100 Avant automatic
sequencer (Applied Biosystems, Foster City, CA, USA).
RNA interference experiments
A pool of commercially available siRNAs speciﬁc for GRAMD3
(NM_001146319, siRNA assays number s35303), ALDH7A1
(NM_001201377.1, s1770) and PHAX (NM_032177.3, s28674; Life
Technologies, Carlsbad, CA, USA) (Supplementary Material,
Table S1 and Fig. S2) were used at ﬁnal concentrations ranging
from 28 to 34 nM to transfect 2.5 × 104 human control primary ﬁ-
broblasts with the Lipofectamine 2000 reagent, according to man-
ufacturer’s instructions (Life Technologies). A scramble siRNAwas
used as negative control (AM 4620, Life Technologies). The experi-
ment was performed twicewith two technical replicates. After 24
h incubation, total RNAwas extracted and retrotranscribed with the
‘TaqMan Cells-to-CT’ kit (Life Technologies). Effective silencing was
evaluated by Real-Time PCR using commercially available TaqMan
assays for GRAMD3 (Hs01597460_m1), ALDH7A1 (Hs00609622_m1)
and PHAX (Hs00536084_m1; Life Technologies) with HMBS gene as
normalizer (Hs00609297_m1). An expression reduction of at least
50% for each gene was considered optimal. Lamin B1 cDNA level
(LMNB1, Hs01059210_m1, Life Technologies) was measured by real-
time PCR using HMBS as normalizer gene (5).
Western blot analysis
Ten percent (wt/vol) brain homogenates from FL and cerebellum
GM and WM of a deceased patient (VI-7, Fig. 1A) and a control
subject were prepared in 0.5% deoxycholic acid/sodium deoxy-
cholate with a protease inhibitor cocktail (Roche Diagnostics,
Mannheim, Germany). Two different samplings for each region
were performed in patient and control with great care to obtain
specimens from similar locations. Total protein concentration
was assessed by BCA assay (Pierce BCA Protein assay kit, Thermo
Scientiﬁc, Rockford, IL, USA). Twentymicrograms of protein sam-
ples were separated by SDS-polyacrylamide gel electrophoresis
(SDS-PAGE) in a 4–12% polyacrylamide gel (Invitrogen, Life Tech-
nologies, Carlsbad, CA, USA). Lamin B1 was detected using a pri-
mary rabbit anti-lamin B1antibody (AB16048, dilution 1:6000,
Abcam) and an enhanced chemiluminescence system (Pierce
ECL plus, Thermo Scientiﬁc). Rabbitmonoclonal anti-alpha tubu-
lin antibody was used as loading control (clone EP1332Y, cat. 04–
1117, dilution 1:500, Merck Millipore, Darmstadt, Germany).
Images were acquired and analyzed using a VersaDoc Imaging
system and the Quantity One software (Bio-Rad, Milan, Italy).
Immunoﬂuorescence
Fibroblasts were plated onto poly-L-lysine-coated coverslips,
serum-deprived for 24 h, ﬁxed in 4% PFA and immunolabeled
as previously described (14). The samples were immunostained
using rabbit polyclonal anti-LB1 (Abcam) or monoclonal anti-
LB1 (Zymed) and counterstained with Hoechst-33342. The con-
focal optical sectioning was performed at room temperature
(RT) using a Leica TCS SP5 AOBS TANDEM inverted confocal
microscope thatwas equippedwith a 40 ×HCX PLAPO 1.25 oil ob-
jective lens.
Atomic forcemicroscopy analysis. For the AFM studies, the ﬁ-
broblasts were analyzed following serum deprivation for 24 h. To
avoid confounding effects of cytoskeletal components and force
dissipation by cytosolic factors, we performed AFM force spec-
troscopy on isolated nuclei that were extracted by osmotic lysis
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of cells with 0.56% KCl for 30 min at RT and spun at 350 × g for
5 min at RT. The nuclei were then re-suspended in PBS and plated
onto a poly-L-lysine-coated petri dish by incubation for 1 h at RT.
AFM in force spectroscopymode (53–55) was performed using the
Nanowizard II AFM (JPK Instruments, Germany) that was
mounted on an Axio Observer D1 inverted optical microscope
(Carl Zeiss, Germany). Nuclear elasticity was probed using spher-
ical polystyrene beads (Ø 4 μm; Polysciences Inc., USA) that were
mounted on silicon tipless cantilevers TL1 (Nanosensors, Switz-
erland) with nominal spring constant of 0.03 N/m. The actual
spring constant of each cantilever was determined using the in
situ thermal noise method (56). The maximum force applied to
the sample was 1 nN. The velocity of the piezo-scanner was
maintained at a constant 3 μm/s. The force curves were corrected
for the bending of the cantilever (57) to calculate the tip-sample
separation and to build force versus indentation (F–I) curves (Sup-
plementary Material, Fig. S1). Nuclear stiffness was computed as
described (58) by calculating the linear ﬁt of the F–I curve between
two speciﬁc force values (i.e. Fo = 250 pN and F1 = 550 pN), corre-
sponding to indentations of ≤1 μm. The force curves were ana-
lyzed using a custom MathLab routine to allow the batch
processing of a set of curves according to the following formula:
stiffness (mN/m) = - ðY1  Y0=X1  X0Þ, where X1 and X0 are the tip-
sample separation in µm, and Y1 and Y0 are the deﬂection in nN
at forces of F1 and F0, respectively. A total of 570 nuclei were ana-
lyzed. Eight-by-eight curve point force spectroscopy maps (64
curves/nucleus) covering an area of 16 μm2 were acquired in the
center of each nucleus using the DirectOverlay routine of the
AFM acquisition software (JPK Instruments, Germany). Stiffness
values between 0.05 and 10 mN/m were accepted (59). Young’s
elastic modulus (E) was calculated as described (60).
Statistical analysis
The statistical analysis between the groupswith normal distribu-
tions was performed using Student’s t-test for two groups. When
the normality test failed, the analysis was performed using non-
parametric tests, such as theMann–Whitney Rank SumTest. The
differences between groups were considered to be statistically
signiﬁcant when P < 0.05.
Circular chromosome conformation capture (4C) assay
Circular Chromosome Conformation Capture was used to search
for interactors of the lamin B1 promoter. The only cells available
were ﬁbroblasts from a single patient (VI-1). Even if the pathology
involves brain, this cell type was considered appropriate for 4C
assay given the overexpression of LMNB1 in this patient’s tissue
(Fig. 1B). A promoter region between two DpnII restriction sites
(chr5:126 112 186–126 112 384; assembly GRCh37/hg19) was se-
lected as a bait. 4C was performed as described elsewhere (36)
with the following modiﬁcations: ﬁbroblasts from subject VI-1
(Fig. 1A) and an healthy sex-matched control were grown in
DMEM supplemented with 10% heat inactivated fetal bovine
serum and 100 µg/ml streptomycin/penicillin to obtain a total
of ∼1 × 107 cells. Cross-linking with formaldehyde (1% v/v) was
performed for 10 min at RT directly in the cell media prior to
quenching with 125 mM glycine. Cells were washed in ice-cold
PBS, trypsinized for 20 min at 37°C, and washed twice in ice-
cold PBS. Cells were lysed for 15 min on ice in 500 µl 10 mM
Tris–HCl pH 8.0, 10 mM NaCl, 0.2% v/v IGEPAL CA-630 supple-
mented with protease inhibitor (Roche Diagnostics). The cell lys-
ate was homogenized with 10 + 10 strokes in a Douncer (‘A’ or
tight pestle) and subsequently transferred in a 1.5 ml tube. Cells
were pelleted for 5 min (4600G at 4°C),washed twice in 500 µl of 1×
DpnII restriction buffer and re-suspended in 600 µl 1.2× DpnII re-
striction buffer. Restriction with DpnII, ligation, crosslink reversal
andDNApuriﬁcationwere carried out asdescribed previously (37).
The 4C library was generated from 100 ng of ligated DNAwith
two successive rounds of PCR ampliﬁcation using two nested
pairs of primers (Supplementary Material, Table S1). The PCR
conditions were as follows. First ampliﬁcation: 20 pmol primers
and 1× Phusion HF mix (New England BioLabs), thermal cycling
conditions were 98°C for 30 s, 35 cycles of 98°C for 10 s, 55°C for
30 s, 72°C for 90 s and a ﬁnal elongation at 72°C for 3 min. Second
ampliﬁcation: a 1:100 dilution of the ﬁrst PCR product was ampli-
ﬁed with 40 pmoles of nested primers at the following thermal
cycling conditions: 94°C for 3 min, 33 cycles of 94°C for 30 s,
65°C for 30 s, 72°C for 90 s and followed by a ﬁnal elongation at
72°C for 3 min. Primersusedduring the second roundof ampliﬁca-
tion have additional nucleotides at their 5′ end (Supplementary
Material, Table S1) that are required for DNA colony ampliﬁcation
on the cluster station as part of the Illumina Genome Analyzer
high-throughput sequencing procedure. The library was gel puri-
ﬁed to reduce the amount of DNA originating from self-ligation of
the DpnII restricted bait. Sequencing was carried out using an
Illumina Genome Analyzer. The sequencing primers were
designed to anneal just upstream to the DpnII (GATC) restriction
site on one side of the bait. Hence all sequences begin with GATC.
The sequences were aligned against the repeat-masked
human genome (build hg18) using the BLAT tool (38). The quality
of the alignments was ﬁltered according to the following criteria:
(i) the minimummatch length was set to 29 nucleotides with no
gap larger than one nucleotide; (ii) alignments had to start with
the DpnII site as the ﬁrst nucleotides. All sequences that did
not ﬁt these criteria or that aligned to more than one location
on the genome were discarded.
Validation of 4C interactors were performed by nested-PCRon
circularized DNA (see Supplementary Material).
Validation of regulatory elements in vitro: luciferase assay
Based on the Illumina results, we selected ﬁve fragments of
∼450 bp centered on the short read sequence. Fragments were
PCR-ampliﬁed under standard conditions with primers contain-
ing a 5′-KpnI restriction site (Supplementary Material, Table S1).
Polymerase chain reaction products were gel puriﬁed with the
HiYield™ Gel/PCR Fragments Extraction Kit (RBC Bioscience),
and inserted into a pTZ57R/T plasmid using the InsTA Cloning
PCR Kit (Invitrogen). Plasmids were transformed using the HIT
DH5A cells (RBC), and extracted using the PureYield Plasmid
Miniprep System (Promega). pTZ57R/T plasmids were digested
with KpnI restriction endonuclease, the insert gel-puriﬁed and li-
gated into the pGL4.10 plasmid with the LMNB1 promoter (long
form, see Supplementary Material). Plasmids were transformed
into JM109 competent cells (Promega) and extracted using the
PureYield Plasmid Midiprep System (Promega). HEK293T
human cells and NH3T3 murine ﬁbroblasts were transiently co-
transfected with a total of 300 ng of pGL4.10 constructs/pGL4.74
(ratio 30:1), and luminescence measured as described above.
For each assay, three independent experiments were performed
in duplicate.
Validation of regulatory elements in vivo: transgenic
mouse enhancer assay
Enhancer region-B (Enh-B; chr5: 125 344 507–125 346 243/hg19)
and -A (Enh-A; chr5: 125 995 897 125 996 243/hg19) were ampliﬁed
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from human genomic DNA by PCR, sequence-validated and
transferred into an Hsp68-LacZ reporter vector. Generation of
transgenic mice and embryo staining was done as previously
described (29) in accordance with protocols approved by the
Lawrence Berkeley National Laboratory. A total of 12 and 17 inde-
pendent transgenic embryos were obtained, respectively, for
regions A and B, and embryos exhibiting LacZ-staining were
scored and annotated independently by multiple curators.
To be deﬁned as a positive enhancer, an element has to show
reproducible expression in the same structure in at least three in-
dependent transgenic embryos, each representing an independ-
ent oocyte injection with random genomic integration.
Genomic landscape of LMNB1 locus with TDs
Topological domain data from genome-wide higher-order chro-
matin interaction data in human embryonic stem cells were
downloaded (http://yuelab.org/hi-c/) andmapped to hg19 coordi-
nates using the UCSC liftover tool (30,61). Topological domain
boundaries (TDBs) are deﬁned as regions of up to 400 kb between
TD regions. We analyzed speciﬁcally the 1.5 Mb region surround-
ing the LMNB1 gene, including the fragment deleted in the ADLD-
1-TO family.
Bioinformatics web resources
The presence of DNaseI hypersensitive regions, TF binding sites,
and histone modiﬁcation variants was evaluated with the UCSC
genome browser (www.genome.ucsc.edu) and using the Inte-
grated Regulation track based on data derived from the ENCODE
project. 4C sequences were aligned against the repeat-masked
human genome (build hg18) using the BLAT tool (62). VISTA En-
hancer browser (enhancer.lbl.gov/) was used to analyze known
enhancer regions.
Supplementary Material
Supplementary Material is available at HMG online.
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